Kite, a Gilead Company, has signed a global license agreement with Refuge Biotechnologies, a synthetic biology company for cancer immunotherapy, for exclusive rights to use latter’s gene expression platform to develop potential treatments for blood cancers.
Gilead Sciences company Kite has secured approval from the European Commission (EC) for Yescarta (axicabtagene ciloleucel) to treat adult patients with diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL).
Personalis has partnered with Duke University and Olink Proteomics for a research collaboration to study the impacts of immunotherapy on advanced gastroesophageal cancer.
The UK National Institute for Health and Care Excellence (NICE) has recommended pembrolizumab (Keytruda) manufactured by MSD to treat melanoma, the most common form of skin cancer.
NeoImmuneTech (NIT) has received Orphan Drug Designation (ODD) from the US Food and Drug Administration (FDA) for NT-I7 (efineptakin alfa) (rhIL-7-hyFc) to treat Glioblastoma Multiforme (GBM), one of the hardest-to-treat cancers.
Boehringer Ingelheim has signed an option to buy Trutino Biosciences, a San Diego-based biotech company.
The National Heart, Lung, and Blood Institute division of the NIH has awarded biotechnology company NovoMedix a $2m Phase II SBIR grant to further the development of novel small molecules that protect patients with triple-negative breast cancer (TNBC) from the long-term cardiotoxic impacts of doxorubicin chemotherapy.
Cornerstone Pharmaceuticals has announced that the European Medicines Agency (EMA) has granted orphan drug designation (ODD) to CPI-613 (devimistat) to treat advanced unresectable biliary tract cancer.
Biotechnology firm Inceptor Bio has raised $37m from Series A funding round that was led by Kineticos Ventures.
Proteros biostructures has expanded its collaboration with AstraZeneca focused on the discovery and development of novel epigenetic drugs.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.